Stockscreener 앱 받기
74.24
1.97%
-1.49
시간 외 거래:
74.24
전일 마감가:
$75.73
열려 있는:
$75.48
하루 거래량:
1.33M
Relative Volume:
1.38
시가총액:
$4.80B
수익:
$1.54B
순이익/손실:
$233.56M
주가수익비율:
22.05
EPS:
3.3669
순현금흐름:
$348.64M
1주 성능:
-7.72%
1개월 성능:
+0.86%
6개월 성능:
+39.47%
1년 성능:
-25.34%
1일 변동 폭
$73.82
$75.77
1주일 범위
$73.82
$81.47
52주 변동 폭
$47.25
$108.91
Lantheus Holdings Inc Stock (LNTH) Company Profile
명칭
Lantheus Holdings Inc
전화
978 671-8001
주소
331 TREBLE COVE ROAD, NORTH BILLERICA, MA
Compare LNTH vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LNTH
Lantheus Holdings Inc
|
74.24 | 4.89B | 1.54B | 233.56M | 348.64M | 3.3669 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.42B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.64B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 44.33B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.51B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 22.84B | 3.18B | 1.33B | 1.04B | 27.90 |
Lantheus Holdings Inc Stock (LNTH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-26 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2025-12-12 | 업그레이드 | Truist | Hold → Buy |
| 2025-10-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-08-12 | 다운그레이드 | Truist | Buy → Hold |
| 2024-12-18 | 개시 | Goldman | Buy |
| 2024-09-03 | 개시 | Redburn Atlantic | Buy |
| 2024-07-10 | 재확인 | JMP Securities | Mkt Outperform |
| 2023-12-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-12-04 | 개시 | TD Cowen | Outperform |
| 2023-09-29 | 개시 | William Blair | Outperform |
| 2023-03-08 | 개시 | JMP Securities | Mkt Outperform |
| 2022-11-30 | 개시 | SVB Leerink | Outperform |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2022-05-09 | 개시 | B. Riley Securities | Buy |
| 2022-04-13 | 개시 | Truist | Buy |
| 2021-02-01 | 개시 | SVB Leerink | Outperform |
| 2020-06-29 | 재개 | Jefferies | Buy |
| 2019-08-16 | 업그레이드 | CJS Securities | Market Perform → Market Outperform |
| 2017-11-02 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-11-08 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-09-23 | 재개 | Credit Suisse | Neutral |
| 2016-02-24 | 재확인 | RBC Capital Mkts | Outperform |
| 2015-12-11 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2015-09-30 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2015-07-20 | 개시 | Credit Suisse | Outperform |
| 2015-07-20 | 개시 | Jefferies | Buy |
| 2015-07-20 | 개시 | RBC Capital Mkts | Outperform |
| 2015-07-20 | 개시 | Robert W. Baird | Outperform |
| 2015-07-20 | 개시 | Wells Fargo | Outperform |
모두보기
Lantheus Holdings Inc 주식(LNTH)의 최신 뉴스
William Blair, Jefferies Maintain LNTH Lantheus Holdings March 2026: Outperform Buy - Meyka
Nuclear Medicine (Radiopharmaceuticals) Market Set for Strong Growth at 9.50% CAGR Through 2034: DelveInsight | Lantheus, GE Healthcare, Novartis, Sotera Health and Others - Barchart.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
CWA Asset Management Group LLC Makes New $1.67 Million Investment in Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Holdings, Inc. (LNTH) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Lantheus to sell SPECT Business to SHINE Technologies - MSN
LNTH Investor Alert: Kessler Topaz Meltzer & Check, LLP Urges LNTH Investors with Losses to Contact the Firm - The National Law Review
Class Action Announcement for Lantheus Holdings, Inc. Investors - The National Law Review
Form DEF 14A LANTHEUS HOLDINGS For: 20 March - Investing.com
Lantheus Holdings, Inc. ($LNTH) Former CEO 2025 Pay Revealed - Quiver Quantitative
[ARS] Lantheus Holdings, Inc. SEC Filing - Stock Titan
Lantheus (NASDAQ: LNTH) 2026 proxy outlines board elections, pay and equity plan - Stock Titan
Lantheus says FDA extended review period for radioactive diagnostic kit - MSN
How Lantheus Holdings Inc. (LNTH) Affects Rotational Strategy Timing - Stock Traders Daily
Lantheus Holdings Inc (LNTH) Trading Down 3.37% on Mar 19 - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Investors to Connect - ACCESS Newswire
Aug Weekly: Will Lantheus Holdings Inc outperform the market in YEAR2026 Key Highlights & Scalable Portfolio Growth Methods - baoquankhu1.vn
Why Lantheus Holdings Stock Popped by Almost 12% Last Month - AOL.com
Lantheus price target raised to $82 from $80 at Truist - MSN
Lantheus Holdings Q4 2025 earnings preview - MSN
Citizens reiterates Lantheus stock rating after FDA extends review By Investing.com - Investing.com Canada
FDA extends review of Lantheus’ neuroendocrine tumor drug By Investing.com - Investing.com South Africa
Lantheus Holdings Inc receives Investment Bank Analyst Rating Update By Investing.com - Investing.com
Lantheus says FDA pushed deadline for reviewing its tumor diagnostic kit application - MSN
Lantheus Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Lantheus stock holds Outperform at William Blair after FDA delay By Investing.com - Investing.com India
Lantheus stock holds Outperform at William Blair after FDA delay - Investing.com
Lantheus Says FDA Pushed Deadline For Reviewing Its Tumor Diagnostic Kit Application - Asianet Newsable
Lantheus (LNTH) Drug Application Review Extended by FDA - GuruFocus
Lantheus Announces Three-Month Extension of PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs) - Bitget
Jefferies Maintains Buy on Lantheus Holdings (LNTH) Mar 17 2026 - Meyka
US FDA extends review of Lantheus' diagnostic imaging kit by three months - Yahoo Finance
FDA extends review of Lantheus’ neuroendocrine tumor drug - Investing.com
Bronstein, Gewirtz & Grossman, LLC Encourages Lantheus Holdings, Inc. (LNTH) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Jefferies raises Lantheus stock price target on PSMA PET outlook By Investing.com - Investing.com Canada
Lantheus Holdings Inc Stock (ISIN: US5156731020) Faces Pressure as Farallon Sells 3.245 Million Shar - AD HOC NEWS
US FDA extends review of Lantheus’ diagnostic imaging kit by three months - 1470 & 100.3 WMBD
Farallon Capital Management LLC Sells 3,245,000 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
2026-03-15 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Investors to Learn More About the Investigation | NDAQ:LNTH | Press Release - Stockhouse
Lantheus Holdings, Inc. (NASDAQ:LNTH) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Lantheus (NASDAQ:LNTH) Lowered to Buy Rating by Wall Street Zen - MarketBeat
How does Lantheus Holdings Inc compare to its peersLayoff News & Community Consensus Trade Alerts - baoquankhu1.vn
FDA approves Lantheus’ PYLARIFY TruVu for prostate cancer imaging - Investing.com Nigeria
Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH - MarketBeat
Lantheus Secures Two FDA Milestones in Four Days: Lutathera Radioequivalent and PSMA PET Upgrade - Oncodaily
Lantheus Holdings (LNTH) Is Up 5.4% After New PYLARIFY TruVu And LUTATHERA ApprovalsHas The Bull Case Changed? - simplywall.st
Why Lantheus (LNTH) Is Up 5.4% After Dual FDA Wins In Radiopharmaceutical Oncology Expansion - Yahoo Finance
Bronstein, Gewirtz & Grossman, LLC Is Investigating Lantheus Holdings, Inc. (LNTH) And Encourages Stockholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Lantheus Holdings, Inc. (LNTH) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Lantheus Stock Analysis: 57% Gain Amid Revenue and Margin ConcernsNews and Statistics - IndexBox
Imaging & Diagnostics Stocks Decline After Q4 2025 EarningsNews and Statistics - IndexBox
Lantheus Holdings Inc (LNTH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.75%
1.88%
자본화:
|
볼륨(24시간):